The medication works by enhancing insulin secretion, suppressing glucagon release, and decreasing appetite through central nervous system pathways
Notably, retatrutide trials showed an overwhelming clearance of liver fat, with some cohorts experiencing up to an 80% reduction in hepatic lipid content, presenting a massive benefit for individuals dealing with metabolic dysfunction-associated steatotic liver disease (MASLD)
Participants continued losing weight throughout 48-68 week studies without needing dose increases
1 Stroke Outcomes Inzucchi presented the stroke outcomes assessed in SOUL, noting that diabetes doubles stroke risk, especially in the presence of elevated A1C
However, following weight loss, the skin may struggle to contract efficiently, resulting in sagging and a prematurely aged appearance